Life science management teams fall victim to recurring mistakes and entrapments. This article discusses avoidable missteps in M&A transactions and their respective remedies.
Published in Life Science Leader, January 2018
Authors: Dr. Oded Ben-Joseph and Thomas Busby
As members of a specialized life sciences investment banking group focused on private equity financing and M&A, we often note that life science management teams fall victim to recurring mistakes and entrapments. Below is a list of avoidable missteps in M&A transactions and their respective remedies.
Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON – July 8, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory […]
Read MoreOutcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?